Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 8;20(10):1341–1352. doi: 10.1038/s41589-024-01612-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 10 — a, Correlation analysis of PCK2 and ACSL4 pT679 expression detected by IHC. The P value was determined using the two- tailed χ² test. b-c, The PCK2 (b) and ACSL4 pT679 (c) expression in pre-treatment biopsies are positively related to clinical response of NPC patients to platinum-based induction chemotherapy. CR, complete response, n = 17; PR, partial response, n = 142; SD, stable disease, n = 23. The P value was determined using the two-tailed χ² test. d, Correlations of locoregional recurrence status with the level of ACSL4 pT679 detected by IHC. The P value was determined using the two-tailed χ² test. e-f, Kaplan-Meier analysis of disease-free survival (h) and overall survival (i) according to the ACSL4 pT679 expression levels. The P values in h-i were determined using the log-rank test. P = 0.0025 and 0.000049. g, Forest plots showing the results of multivariate Cox regression analysis, indicated that ACSL4 pT679 expression is a significant prognostic indicator for overall survival in NPC patients (Cox proportional-hazards model). pACSL4(T679) level (High vs. Low: HR = 0.219–0.631), gender (Male vs. Female: HR = 1.163–3.777), WHO type (III vs. II: HR = 0.206–0.887) and TNM stage (IV vs. III: HR = 1.252–2.886). h, Kaplan-Meier analysis of distant metastasis-free survival according to the ACSL4 pT679 expression levels. The P value was determined using the log-rank test.

Source data